Blood biomarkers differentiate AD-related versus non-AD-related cognitive deficits.

ABSTRACT:

Introduction

The utility of blood-based biomarkers for discriminating Alzheimer's disease (AD)-related versus non-AD-related cognitive deficits in preclinical populations remains poorly understood. Here, we tested the capability of blood markers to detect and discriminate variation in performance across multiple cognitive domains in a cognitively unimpaired sample.

Methods

Participants (n = 648, aged 69.9 ± 3.8, 71% female) underwent a comprehensive cognitive assessment and assays for plasma-based biomarkers amyloid beta (Aβ)1-42/1-40 by mass spectrometry, phosphorylated tau (p-tau) 181 and 217, p-tau217/Aβ1-42, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).

Results

Greater p-tau217 was exclusively associated with poorer episodic memory perform

SUBMITTER: Sewell KR 

PROVIDER: S-EPMC11923558 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature